Could a heart pill boost exercise capacity in chronic heart failure?

NCT ID NCT07697365

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study looks at whether vericiguat, a drug that stimulates a key enzyme, can improve exercise ability and heart pressure during activity in people with chronic heart failure and reduced ejection fraction. Participants take vericiguat alongside their usual heart medications and undergo exercise tests and heart catheterization at the start and after 12 months. The goal is to see if the drug helps the heart handle exercise better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
vericiguat
What this could lead to
If vericiguat improves exercise tolerance and heart pressures during activity, it could become a standard add-on treatment for heart failure patients already on other therapies.
What could go wrong
This is a small observational study with only 40 participants, so results may not apply to all heart failure patients. Vericiguat may cause low blood pressure or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alexandra General Hospital

    Athens, Attica, 11528, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.